Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference14 articles.
1. Syed YY. Lorlatinib: First Global Approval. Drugs. 2019;79(1):93–8.
2. Pfizer Inc. LORBRENA® (lorlatinib): Prescribing information. 2021. http://labeling.pfizer.com/ShowLabeling.aspx?id=11140. Accessed 17 Jan 2021.
3. European Medicines Agency. Lorviqua (lorlatinib). 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua. Accessed 17 Jan 2021.
4. Johnson TW, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–44.
5. Basit S, et al. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib. Eur J Med Chem. 2017;134:348–56.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献